GALDY
Galderma Group AG$46.15 −0.15 (−0.32%)
Oct 26 4:00 PM ET · prev $46.30
Median target
🔒 Subscribers only
1 year
+31.9%
from $34.98 · Oct 27
30 days
+18.0%
from $39.10
52-week range
$34.98–46.30
−0% from high · low Oct 27
Avg volume 20D
160.9K
Oct 16 spike 558.4K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 31 Short interest jumps 53.5% to 25.5K
- E Sep 14 Trial readout: T-90d Trial Readout: nemolizumab (Phase 2)
- X Sep 30 Short interest jumps 323.7% to 72.3K
- E Oct 2 Trial readout: T-90d Trial Readout: Trifarotene (Phase 3)
- E Oct 5 Trial readout: T-90d Trial Readout: Trifarotene (Phase 3)
- E Oct 12 Trial readout: T-90d Trial Readout: Trifarotene (Phase 3)
- E Oct 19 Trial readout: T-90d Trial Readout: Trifarotene (Phase 3)
- E Oct 20 Trial readout: Results Pending: Nemolizumab (Phase 3) — Completed 50d ago
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 0 trimmed or exited.
- TrendUPTREND
14% above its 50-day average. New closing high $46.30 on Oct 23.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| RHUMBLINE ADVISERS | ADD | $1.4M |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | $146.6K |
| RHUMBLINE ADVISERS | DOUBLED | $878.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trial readout
🔒 Fresh data, subscribers only
Oct 20, 2026
Trial readout
Results Pending: Nemolizumab (Phase 3) — Completed 50d ago
Trial: Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Sponsor: Galderma R&D Phase: Phase 3 | Completed…
Oct 18, 2026
Trial readout
T-90d Trial Readout: Trifarotene (Phase 3)
Trial: A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Sponsor…
Oct 12, 2026
Trial readout
T-90d Trial Readout: Trifarotene (Phase 3)
Trial: A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Sponsor…
Oct 4, 2026
Trial readout
T-90d Trial Readout: Trifarotene (Phase 3)
Trial: A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Sponsor…
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Jun 30, 2026 Inst.
RHUMBLINE ADVISERS — ADD
30,607 shares ($1.4M)
Jun 30, 2026 Inst.
PNC FINANCIAL SERVICES GROUP, — ADD
3,224 shares ($146.6K)
May 22, 2026 Event
DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE)
Original Approval — Type 8 - Partial Rx to OTC Switch — ADAPALENE AND BENZOYL PEROXIDE — GEL — TOPIC